Burbach G J, Bienzle U, Neuhaus R, Hopf U, Metzger W G, Pratschke J, Neuhaus P
Institute of Tropical Medicine, Engeldamm, Berlin, Germany.
Transplantation. 1997 Feb 15;63(3):478-80. doi: 10.1097/00007890-199702150-00027.
To prevent reinfection with hepatitis B virus after orthotopic liver transplantation, patients receive long-term intravenous anti-HBs immunoprophylaxis. We compared the pharmacokinetics of intravenously and intramuscularly administered commercially available hepatitis B virus immunoglobulins. The study group consisted of 12 patients on immunoprophylaxis after orthotopic liver transplantation, who were Hbs antigen negative; 11 were anti-HBe positive and one was HBe positive. The patients first received intravenous immunoglobulin, and six of them were then transferred to intramuscular immunoglobulin. Our findings show that with fortnightly intramuscular application of 1000 IU of anti-HBs, reproducible and stable antibody titers above 100 IU of anti-HBs can be achieved. Side effects of intramuscular immunoprophylaxis are minimal and the method is safe. The switch from intravenous (1500 IU of anti-HBs) to intramuscular (1000 IU of anti-HBs) reduced the cost of immunoprophylaxis by more than 50%.
为预防原位肝移植后乙肝病毒再感染，患者需接受长期静脉注射抗-HBs免疫预防治疗。我们比较了静脉注射和肌肉注射市售乙肝免疫球蛋白的药代动力学。研究组由12例原位肝移植后接受免疫预防治疗的患者组成，这些患者乙肝表面抗原阴性；11例抗-HBe阳性，1例HBe阳性。患者首先接受静脉注射免疫球蛋白，其中6例随后转为肌肉注射免疫球蛋白。我们的研究结果表明，每两周肌肉注射1000 IU抗-HBs，可使抗-HBs抗体滴度稳定维持在100 IU以上。肌肉注射免疫预防的副作用极小，该方法安全可靠。从静脉注射（1500 IU抗-HBs）转为肌肉注射（1000 IU抗-HBs）可使免疫预防成本降低50%以上。
